Background Increasing use of BRCA1/2 testing for tailoring cancer treatment and extension
of testing to tumour tissue for somatic mutation is moving BRCA1/2 mutation screening from …

Hereditary cancer syndromes are inherited pathogenic genetic variants that significantly
increase the risk of developing cancer. When individuals become aware of their increased …

Background Identification of BRCA mutations in breast cancer (BC) patients influences
treatment and survival and may be of importance for their relatives. Testing is often restricted …

Background Sequence-based BRCA testing can identify variants of unknown significance
(VUS). Relatively little is known about how well a test outcome of VUS is understood by …

Variants of uncertain significance (VUS) are a well‐recognized source of uncertainty in
genomic medicine. Despite the existence of straightforward clinical management …

Background In recent years, the amount of genomic data produced in clinical genetics
services has increased significantly due to the advent of next-generation sequencing. This …

Genetic testing of patients with cancer is increasingly offered to guide management,
resulting in a growing need for oncology health professionals to communicate genetics …

Context.—Molecular diagnostics play a role in the management of many cancers, including
breast cancer. Objective.—To provide an update on molecular testing in current clinical …

As genetic testing for hereditary cancer syndromes has transitioned from research to clinical
settings, research regarding its accompanying psychosocial effects has grown. Men and …

Objective Patients' psychological reactions to multigene cancer panel testing might differ
compared with the single‐gene testing reactions because of the complexity and uncertainty …